NASDAQ$BMEA
Biomea Fusion Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported fourth quarter and full year results, highlighting progress in diabetes and oncology programs.
Biomea Fusion reported a net loss of $34.9 million for Q4 2023 and ended the quarter with $177.2 million in cash, cash equivalents, and restricted cash. The company highlighted positive data from its Phase 2 trial in type 2 diabetes and the initiation of a Phase 2 study in type 1 diabetes.
- Reported Phase 2 data in type 2 diabetes patients supporting the disease-modifying potential of BMF-219.
- Initiated a Phase 2 study of BMF-219 in type 1 diabetes patients.
- Reported initial topline data from Phase 1 study of BMF-219 in acute myeloid leukemia (AML).
- Ended the fourth quarter of 2023 with a cash position of $177.2 million.
Headline financials
Revenue & EPS history
Biomea Fusion · Revenue · Quarterly
$6.14M
Forward guidance
Biomea Fusion anticipates key milestones in 2024, including completing enrollment and reporting data from Phase 2 trials in type 2 and type 1 diabetes, advancing oncology programs, and announcing a third development candidate.
Tailwinds
- Complete and report the results of dosing and follow-up of over 200 type 2 diabetes patients enrolled in Phase 2 expansion cohorts.
- Report data from 40 patients enrolled in the open label portion of Phase 2 study in type 1 diabetes patients.
- Complete dose escalation steps in liquid and solid tumor studies of BMF-219 and BMF-500.
- Establish recommended Phase 2 dose (RP2D) for COVALENT-101 in liquid tumors.
- Announce a third development candidate from the Biomea FUSION™ Platform technology.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2023
+5.2%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+3.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+109.7%
Q4 2022
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +15.3% | -13.5% | -23.7% | |
| Q3 2025 | -0.7% | -4.3% | -21.0% | |
| Q2 2025 | +0.6% | -3.2% | +21.5% | |
| Q1 2025 | -1.3% | -4.6% | +73.0% | |
| Q4 2024 | +1.2% | -7.8% | -8.7% | |
| Q3 2024 | -16.7% | -27.2% | -43.4% | |
| Q1 2024 | +6.7% | +3.7% | -9.1% | |
| Q4 2023 | -14.4% | -14.8% | -22.6% | |
| Q3 2023 | -6.8% | -7.9% | +16.3% | |
| Q2 2023 | -2.4% | -9.3% | -22.2% | |
| Q1 2023 | -3.3% | +2.6% | +12.5% | |
| Q4 2022 | +109.7% | +101.0% | +84.6% | |
| Q3 2022 | -15.6% | -29.4% | -43.3% | |
| Q2 2022 | +3.3% | +11.8% | +8.5% | |
| Q1 2022 | +35.2% | +69.4% | +127.2% | |
| Q4 2021 | -13.8% | -7.7% | -36.2% | |
| Q3 2021 | +7.6% | +2.0% | -7.9% | |
| Q2 2021 | -0.6% | -11.0% | -3.4% | |
| Q1 2021 | -0.3% | +7.9% | -21.4% | |
| Q4 2020 | -0.3% | +7.9% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro